EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$3.24
+0.04 (+1.25%)
Financial Highlights (FY 2026)
Revenue
72.02M
Net Income
-284,500,802
Gross Margin
—
Profit Margin
-395.0%
Rev Growth
+27.2%
D/E Ratio
2.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.4% | 64.4% |
| Operating Margin | -394.9% | -355.4% | 24.8% | 21.2% |
| Profit Margin | -395.0% | -375.3% | 14.4% | 17.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 72.02M | 56.65M | 30.54M | 27.97M |
| Gross Profit | — | — | 19.66M | 18.00M |
| Operating Income | -284,416,841 | -201,317,465 | 7.57M | 5.94M |
| Net Income | -284,500,802 | -201,376,894 | 4.38M | 4.75M |
| Gross Margin | — | — | 64.4% | 64.4% |
| Operating Margin | -394.9% | -355.4% | 24.8% | 21.2% |
| Profit Margin | -395.0% | -375.3% | 14.4% | 17.0% |
| Rev Growth | +27.2% | +27.2% | +16.6% | +5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 144.76M | 144.76M | 59.55M | 55.44M |
| Total Equity | 67.40M | 67.40M | 93.22M | 102.72M |
| D/E Ratio | 2.15 | 2.15 | 0.64 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -275,036,371 | -205,493,159 | 9.59M | 9.00M |
| Free Cash Flow | — | — | 5.15M | 6.45M |